FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 359:1977-1981 November 6, 2008 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Britain's National Institute for Health and Clinical Excellence, known as NICE, is an independent, government-funded organization that advises the British National Health Service (NHS).¹ Established in 1999, the institute has recommended coverage for hundreds of medicines. Since 2002, NHS organizations in England and Wales have been required to pay for medicines and treatments recommended in NICE "technology appraisals." The NHS usually does not provide medicines or treatments that are not recommended by NICE — although exceptions are possible.

NICE (www.nice.org.uk), however, has been criticized for the slow release of its appraisals, which has delayed the availability of some . . . [Full Text of this Article]

Source Information

Dr. Steinbrook (rsteinbrook@attglobal.net) is a national correspondent for the Journal.

This article has been cited by other articles:

• Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., Manns, B. J. (2009). Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions: A Comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443 [Abstract] [Full Text]  
• Knauf, F., Aronson, P. S. (2009). ESRD as a Window into America's Cost Crisis in Health Care. J. Am. Soc. Nephrol. 20: 2093-2097 [Full Text]  
• Outterson, K., Kesselheim, A. S. (2009). How Medicare Could Get Better Prices On Prescription Drugs. Health Aff (Millwood) 28: w832-w841 [Abstract] [Full Text]  
• Kelly, C. J, Mir, F. A (2009). Economics of biological therapies. BMJ 339: b3276-b3276 [Full Text]  
• Messori, A., Trippoli, S., Bonacchi, M., Sani, G. (2009). Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement.. J. Thorac. Cardiovasc. Surg. 138: 480-485 [Abstract] [Full Text]  
• Hillner, B. E., Smith, T. J. (2009). Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing. JCO 27: 2111-2113 [Full Text]  
• Horvitz-Lennon, M., Donohue, J. M., Domino, M. E., Normand, S.-L. T. (2009). Improving Quality And Diffusing Best Practices: The Case Of Schizophrenia. Health Aff (Millwood) 28: 701-712 [Abstract] [Full Text]  
• Marmor, T., Oberlander, J., White, J. (2009). The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality. ANN INTERN MED 150: 485-489 [Abstract] [Full Text]  
• Bach, P. B. (2009). Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. NEJM 360: 626-633 [Full Text]  
• Beard, K. (2008). Commentary: The balance between marketing and safety. BMJ 337: a2996-a2996 [Full Text]